AZ suffers Australian Crestor patent setback, could up M&A pressure
This article was originally published in Scrip
Executive Summary
An unexpected court ruling from Australia invalidating patents on AstraZeneca's top drug, Crestor (rosuvastatin) will up pressure on the firm to dabble in further M&A, according to analysts, who have downgraded their core-EPS forecast for the firm. The company announced the news on 5 March.